AEterna starts Phase III trial

AEterna Laboratories (TSE:AEL; AELA) started recruiting for a 760-patient U.S. and Canadian Phase III trial of AE-941/Neovastat to treat inoperable non-small-cell lung cancer. This is the second Phase...